Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BCT022
MIFTS: 63

Bacterial Infectious Disease

Categories: Infectious diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Bacterial Infectious Disease

About this section

MalaCards integrated aliases for Bacterial Infectious Disease:

Name: Bacterial Infectious Disease 12 15
Bacterial Infections 45

Classifications:

MalaCards categories:
Global: Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:104
MeSH 45 D001424
NCIt 51 C2890
SNOMED-CT 69 87628006
ICD10 34 A49 A49.9
UMLS 74 C0004623
Sources

Summaries for Bacterial Infectious Disease

About this section
Disease Ontology : 12 A disease by infectious agent that results in infection, has material basis in Bacteria.

MalaCards based summary : Bacterial Infectious Disease, also known as bacterial infections, is related to commensal bacterial infectious disease and primary bacterial infectious disease. An important gene associated with Bacterial Infectious Disease is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Meropenem and Imipenem have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and colon, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Sources

Related Diseases for Bacterial Infectious Disease

About this section

Diseases related to Bacterial Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 716)
# Related Disease Score Top Affiliating Genes
1 commensal bacterial infectious disease 34.6 IL10 IL1B IL6 TNF
2 primary bacterial infectious disease 34.1 CRP CXCL8 IFNG IL10 IL17A IL1B
3 myd88 deficiency 33.9 IRAK4 MYD88 TLR2 TLR4
4 irak4 deficiency 32.5 IRAK4 MYD88 TLR2 TLR4
5 osteomyelitis 32.4 CXCL8 IFNG IL10 IL1B IL6 TNF
6 trench fever 32.4 TLR2 TLR4 TNF
7 bacterial pneumonia 32.4 CRP CXCL8 DEFB4A IL17A IL6 TLR4
8 campylobacteriosis 32.4 IFNG IL1B TLR4
9 pyelonephritis 32.4 CRP CXCL8 IL10 IL1B IL6 TLR4
10 bacterial meningitis 32.4 CRP CXCL8 IL10 IL1B IL6 TLR2
11 spotted fever 32.3 IFNG IL10 TNF
12 bacterial sepsis 32.2 CRP CXCL8 IL10 TLR4 TNF
13 shigellosis 32.2 CAMP CXCL8 IL10 IRAK4
14 legionellosis 32.2 IL1B MYD88 TLR2 TLR4 TNF
15 pertussis 32.2 IL10 IL1B IL6 TLR4 TNF
16 leprosy 3 32.2 IFNG IL10 NOD2 TLR2 TNF
17 meningitis 32.2 CRP CXCL8 IFNG IL10 IL1B IL6
18 chorioamnionitis 32.2 CRP CXCL8 IL1B IL6 TLR4 TNF
19 typhoid fever 32.2 CRP IFNG IL1B IL6 TLR4 TNF
20 lyme disease 32.1 CRP IL17A IL1B IL6 TLR2 TNF
21 pyelitis 32.1 CRP CXCL8 IL6 TLR4
22 pyoderma 32.1 CXCL8 NOD2 TNF
23 pyoderma gangrenosum 32.1 CXCL8 NOD2 TNF
24 salmonellosis 32.0 DEFB1 DEFB4A IFNG IL18 IL1B TLR4
25 tonsillitis 32.0 CXCL8 DEFB1 DEFB4A IFNG IL1B IL6
26 leptospirosis 32.0 CRP CXCL8 IFNG IL10 IL1B IL6
27 brucellosis 31.9 CRP CXCL8 IFNG IL10 IL18 IL6
28 q fever 31.9 IFNG IL10 IL1B IL6 NOD2 TLR2
29 guttate psoriasis 31.9 CAMP NOD2
30 melioidosis 31.9 IFNG IL10 IL18 IL6 TLR2 TLR4
31 chlamydia 31.9 CRP CXCL8 IFNG IL10 IL1B IL6
32 mycobacterium tuberculosis 1 31.9 IFNG IL10 IL17A IL18 MYD88 TLR2
33 toxic shock syndrome 31.8 CXCL8 IFNG IL10 IL1B IL6 TLR2
34 bronchitis 31.0 CRP CXCL8 TNF
35 cystic fibrosis 30.9 CAMP CXCL8 DEFB1 DEFB4A TLR4
36 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.9 IFNG IL10 IL17A
37 hematopoietic stem cell transplantation 30.9 IFNG IL10 IL6 TNF
38 leishmaniasis 30.8 IFNG IL10 IL1B TLR2 TLR4 TNF
39 autoimmune disease 30.8 IFNG IL10 IL17A IL1B IL6 TNF
40 dermatitis 30.8 IFNG IL17A IL18 NOD2
41 peritonitis 30.8 CRP CXCL8 IL10 IL1B IL6 TLR2
42 endocarditis 30.7 CRP CXCL8 IL10 IL6 TLR2 TNF
43 human immunodeficiency virus infectious disease 30.7 IFNG IL10 IL6 TNF
44 pulmonary disease, chronic obstructive 30.7 CRP CXCL8 IL17A IL6 TLR2 TNF
45 infective endocarditis 30.7 CRP IL6 TLR2 TNF
46 haemophilus influenzae 30.7 CXCL8 IL1B TLR2 TNF
47 arthritis 30.7 CXCL8 IFNG IL10 IL17A IL18 IL1B
48 acquired immunodeficiency syndrome 30.6 IFNG IL10 IL1B IL6 TNF
49 viral pneumonia 30.6 CRP IL17A IL6
50 mastitis 30.6 CXCL8 IL17A IL6 NOD2 TLR2

Graphical network of the top 20 diseases related to Bacterial Infectious Disease:



Diseases related to Bacterial Infectious Disease
Sources

Symptoms & Phenotypes for Bacterial Infectious Disease

About this section

GenomeRNAi Phenotypes related to Bacterial Infectious Disease according to GeneCards Suite gene sharing:

27 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.88 CXCL8 IL10 IL17A IL18 IL1B MYD88
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.88 CXCL8 IL10 IL17A IL18 IL1B MYD88
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.73 NOD2
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.73 CRP
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.73 IL10
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.73 IL10
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.73 CRP
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.73 IL10
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.73 IL10
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.73 CRP IL10 NOD2 TLR4
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.73 CRP

MGI Mouse Phenotypes related to Bacterial Infectious Disease:

47 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.36 CAMP CSF3 IFNG IL10 IL17A IL18
2 immune system MP:0005387 10.33 CAMP CRP CSF3 IFNG IL10 IL17A
3 homeostasis/metabolism MP:0005376 10.28 CRP IFNG IL10 IL17A IL18 IL1B
4 cellular MP:0005384 10.24 CAMP IFNG IL10 IL18 IL6 IRAK4
5 cardiovascular system MP:0005385 10.21 CRP IFNG IL10 IL18 IL1B IL6
6 digestive/alimentary MP:0005381 10.18 IFNG IL10 IL17A IL18 IL6 MYD88
7 integument MP:0010771 10.02 CSF3 IFNG IL10 IL18 IL1B IL6
8 neoplasm MP:0002006 9.97 IFNG IL10 IL1B IL6 MYD88 TLR2
9 renal/urinary system MP:0005367 9.8 CSF3 IFNG IL17A IL6 MYD88 TLR2
10 respiratory system MP:0005388 9.76 IFNG IL10 IL17A IL6 MYD88 TLR2
11 skeleton MP:0005390 9.65 IFNG IL10 IL17A IL1B IL6 MYD88
12 vision/eye MP:0005391 9.23 CAMP IFNG IL10 IL18 IL6 MYD88
Sources

Drugs & Therapeutics for Bacterial Infectious Disease

About this section

Drugs for Bacterial Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 967)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Meropenem Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 119478-56-7, 96036-03-2 441130 64778
2
Imipenem Approved Phase 4,Phase 3,Phase 2,Phase 1 74431-23-5, 64221-86-9 104838
3
Ertapenem Approved, Investigational Phase 4,Phase 3,Phase 2 153832-46-3 150610
4
Cefotaxime Approved Phase 4,Phase 3,Phase 2,Phase 1 63527-52-6 456256 5742673
5
Vancomycin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1404-90-6 441141 14969
6
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85721-33-1 2764
7
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83905-01-5 55185 447043
8
Clavulanate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58001-44-8 5280980
9
Cefoxitin Approved Phase 4,Phase 2,Phase 1 35607-66-0 441199
10
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 26787-78-0 33613
11
Metronidazole Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 443-48-1 4173
12
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 117976-89-3 5029
13
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81103-11-9 84029
14
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 616-91-1 12035
15
Sulbactam Approved Phase 4,Phase 3,Phase 2 68373-14-8
16
Piperacillin Approved Phase 4,Phase 3,Not Applicable 66258-76-2 43672
17
Polymyxin B Approved, Vet_approved Phase 4,Phase 3,Phase 2 1404-26-8
18
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
19
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
20
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
21
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
22
Rifampicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 13292-46-1 5381226 5458213
23
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103577-45-3 3883
24
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 138530-94-6, 103577-45-3 9578005
25
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 73590-58-6 4594
26
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
27
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 93-14-1 3516
28
Pantoprazole Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 102625-70-7 4679
29
Cefazolin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 25953-19-9 656510 33255
30
Daptomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103060-53-3 16129629
31
Teicoplanin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61036-62-2
32
Ofloxacin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 82419-36-1 4583
33
Levofloxacin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 100986-85-4 149096
34
Mupirocin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 12650-69-0 446596
35
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 18323-44-9 29029
36
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757
37
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-63-6 5991
38
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
39
Desogestrel Approved Phase 4 54024-22-5 40973
40
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
41
Tinidazole Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 19387-91-8 5479
42
Tetracycline Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 60-54-8 5353990
43
Cloxacillin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 61-72-3 6098
44
Pyrazinamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 98-96-4 1046
45
Ethambutol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 74-55-5 3279 14052
46
Isoniazid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 54-85-3 3767
47 Cranberry Approved, Investigational Phase 4,Phase 2,Not Applicable
48
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 22916-47-8 4189
49
Clotrimazole Approved, Vet_approved Phase 4,Phase 3 23593-75-1 2812
50
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865

Interventional clinical trials:

(show top 50) (show all 4763)
# Name Status NCT ID Phase Drugs
1 Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections Unknown status NCT01297842 Phase 4 Ertapenem;Meropenem or Imipenem
2 Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
3 Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy Unknown status NCT01572597 Phase 4 10RAC+acetylcystein;10RAC+metronidazole
4 Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection Unknown status NCT01760109 Phase 4 Piperacillin Sodium and Sulbactam Sodium
5 Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection Unknown status NCT01897831 Phase 4 xin te mie
6 Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria Unknown status NCT02328183 Phase 4 Polymyxin B
7 Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children Unknown status NCT00494624 Phase 4 prednisolone
8 Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin Unknown status NCT02443064 Phase 4 Vancomycin
9 Role of N-Acetylcysteine in Treatment of Bacterial Vaginosis Unknown status NCT01841411 Phase 4 N-Acetyl cysteine;Metronidazole + N-Acetyl cysteine;metronidazole
10 10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication Unknown status NCT03134378 Phase 4 Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg
11 Helicobacter Pylori Eradication Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
12 Tailored Therapy for Helicobacter Pylori in Children Unknown status NCT02635191 Phase 4 Tailored Group;Standard group
13 Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole Unknown status NCT02552641 Phase 4 Esomeprazole;Amoxicillin;Clarythromycin
14 Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
15 Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection Unknown status NCT02237859 Phase 4 Vancomycin
16 Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy Unknown status NCT02108184 Phase 4 Sequential therapy 10 days;Sequential therapy 14 days;Concomitant therapy 10 days;Concomitant therapy 14 days
17 Vascular Surgical Antibiotic Prophylaxis Study (VSAPS 2) Unknown status NCT01612052 Phase 4 Antibiotic Prophylaxis
18 Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections Unknown status NCT01566643 Phase 4 RA5-RACM7;RA3-RACM7;RA7-RACM7
19 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
20 Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy Unknown status NCT01265069 Phase 4 high dose dual therapy;concomitant therapy
21 A Trial to Evaluate the Loading Dose Required to Achieve Therapeutic Serum Teicoplanin Concentration Timely Unknown status NCT00368498 Phase 4 teicoplanin
22 Community-based Helicobacter Pylori Eradication Unknown status NCT00155389 Phase 4 Helicobacter pylori eradication
23 Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) Unknown status NCT02569632 Phase 4
24 Topical Gentamicin Cream Versus Alternating Gentamicin and Mupirocin Cream in Peritoneal Dialysis Unknown status NCT00751374 Phase 4 gentamicin;gentamicin cream alternating with mupirocin cream
25 The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet Treatment of Bacterial Vaginosis Unknown status NCT03080740 Phase 4 Clindamycin palmitate hydrochloride dispersible tablet;Metronidazole Tablet
26 Probiotic Versus Placebo as Adjuvant for Bacterial Vaginosis Treatment During Pregnancy Unknown status NCT01558388 Phase 4 Lactobacillus acidophilus;Placebo
27 Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers Unknown status NCT01448291 Phase 4 Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
28 Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment Unknown status NCT02988089 Phase 4 Clarithromycin susceptibility dependant strategy;2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline );proton pump inhibitor (PPI) and Colloidal Bismuth Pectin;amoxicillin and clarithromycin or amoxicillin and furazolidone;amoxicillin and furazolidone or amoxicillin and tetracycline;amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
29 Rifampin Combination Therapy Versus Monotherapy in Early Staphylococcal Infections After Total Hip and Knee Arthroplasty Unknown status NCT00423982 Phase 4 Rifampin-combination therapy;Monotherapy
30 Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes Unknown status NCT01782950 Phase 4 Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
31 Probiotics Capsule as Supplemental Therapy for Group B Streptococci Infection and Vaginitis During Pregnancy Unknown status NCT01779193 Phase 4
32 Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia Unknown status NCT00990405 Phase 4 Lansoprzole+Amoxicillin+Clarithromycin
33 NAT2 in Re-challenge of INH in Patients With Hepatitis Unknown status NCT00728546 Phase 4 Isoniazid (Rifinah)
34 Use TST and QFT-RD1 Test to Monitor the Tuberculous Infection in Patients, Close Contact People and Health Care Workers Unknown status NCT00311220 Phase 4 tuberculin for skin test
35 Randomized Controlled Trial of Percutaneous and Intradermal BCG Vaccination. Unknown status NCT00242047 Phase 4
36 Ciprofloxacin for Prevention of BK Infection Unknown status NCT01789203 Phase 4 Ciprofloxacin;placebo
37 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Unknown status NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
38 The Efficacy of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease Unknown status NCT01469702 Phase 4 prednison and azithromycin;prednison, azithromycin;prednison, Azenil
39 Influence of BCG on TDaP-IPV Vaccination Unknown status NCT02771782 Phase 4
40 Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand Unknown status NCT02408926 Phase 4
41 Pertussis (Tdap) Vaccination in Pregnancy Unknown status NCT01698346 Phase 4
42 The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients Unknown status NCT00336115 Phase 4
43 Typhoid Fever: Combined vs. Single Antibiotic Therapy Unknown status NCT02224040 Phase 4 ceftriaxone;ceftriaxone and azithromycin;azithromycin;azithromycin and cefixime
44 Rationale, Design and Methods for the Early Surgery in Infective Endocarditis Study (ENDOVAL) Unknown status NCT00624091 Phase 4
45 SDD for Eradicating CRKP Carriage Unknown status NCT01761487 Phase 4
46 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis Unknown status NCT01223976 Phase 4
47 An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster Unknown status NCT00870350 Phase 4
48 The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Unknown status NCT02588196 Phase 4 Dexamethasone acetate
49 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
50 Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old. Unknown status NCT01478035 Phase 4 Phenytoin;placebo

Search NIH Clinical Center for Bacterial Infectious Disease

Cochrane evidence based reviews: bacterial infections

Sources

Genetic Tests for Bacterial Infectious Disease

About this section
Sources

Anatomical Context for Bacterial Infectious Disease

About this section

MalaCards organs/tissues related to Bacterial Infectious Disease:

42
Skin, Testes, Colon, Lung, Liver, Heart, Eye
Sources

Publications for Bacterial Infectious Disease

About this section

Articles related to Bacterial Infectious Disease:

(show top 50) (show all 2362)
# Title Authors Year
1
Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology. ( 30148440 )
2019
2
Treatment of late bacterial infections resulting from soft-tissue filler injections. ( 30863129 )
2019
3
Animal models of orthopaedic infections. A review of rabbit models used to induce long bone bacterial infections. ( 30875284 )
2019
4
Cross-Talk Between Antigen Presenting Cells and T Cells Impacts Intestinal Homeostasis, Bacterial Infections, and Tumorigenesis. ( 30894857 )
2019
5
Guanylate-binding proteins at the crossroad of noncanonical inflammasome activation during bacterial infections. ( 30897250 )
2019
6
How to predict serious bacterial infections in young febrile infants in the emergency department? ( 30904453 )
2019
7
Impact of donor with evidence of bacterial infections on deceased donor liver transplantation: a retrospective observational cohort study in Taiwan. ( 30904845 )
2019
8
Bacterial Infections Associated with Viperidae Snakebites in Children: A 14-Year Experience at the Hospital Nacional de Niños de Costa Rica†. ( 30915952 )
2019
9
Predicting Serious Bacterial Infections in Febrile Young Infants Utilizing Body Temperature. ( 30859661 )
2019
10
The Efficacy of Aminomethyl Spectinomycins against Complex Upper Respiratory Tract Bacterial Infections. ( 30858215 )
2019
11
First Case of Patient With Two Homozygous Mutations in MYD88 and CARD9 Genes Presenting With Pyogenic Bacterial Infections, Elevated IgE, and Persistent EBV Viremia. ( 30837984 )
2019
12
Acid Sphingomyelinase-Ceramide System in Bacterial Infections. ( 30816675 )
2019
13
A Toll-like receptor 2 genetic variant modulates occurrence of bacterial infections in patients with sickle cell disease. ( 30908604 )
2019
14
Procalcitonin as a biomarker to differentiate bacterial infections from engraftment syndrome following autologous hematopoietic stem cell transplantation for multiple myeloma. ( 30549311 )
2019
15
Diagnosis of periprosthetic joint bacterial infections by culture of sonication fluid from infected implants. ( 30803320 )
2019
16
Impact of Delayed Therapy in Serious Bacterial Infections: Role of Technology and the Clinician at the Bedside. ( 30797500 )
2019
17
Current Challenges and Perspectives for the Use of Aqueous Plant Extracts in the Management of Bacterial Infections: The Case-Study of Salmonellaenterica Serovars. ( 30795544 )
2019
18
Inducible lung epithelial resistance requires multisource reactive oxygen species generation to protect against bacterial infections. ( 30794556 )
2019
19
A Clinical Prediction Rule to Identify Febrile Infants 60 Days and Younger at Low Risk for Serious Bacterial Infections. ( 30776077 )
2019
20
Optimal antimicrobial duration for common bacterial infections. ( 30765902 )
2019
21
Interest of Eosinophil Count in Bacterial Infections to Predict Antimicrobial Therapy Efficacy. ( 30758492 )
2019
22
Interest of Eosinophil Count in Bacterial Infections to Predict Antimicrobial Therapy Efficacy-Reply. ( 30758488 )
2019
23
Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections. ( 30723876 )
2019
24
The global dissemination of bacterial infections necessitates the study of reverse genomic epidemiology. ( 30715167 )
2019
25
Mixed Viral-Bacterial Infections and Their Effects on Gut Microbiota and Clinical Illnesses in Children. ( 30696865 )
2019
26
Non-critical healthcare tools as a potential source of healthcare-acquired bacterial infections in eastern Ethiopia: A hospital-based cross-sectional study. ( 30693084 )
2019
27
Deciphering the Role of Intramolecular Networking in Cholic Acid-Peptide Conjugates (CAPs) at Lipopolysaccharide Surface in Combating Gram-negative Bacterial Infections. ( 30688460 )
2019
28
Limitations of diagnostic tests for bacterial infections. ( 30686500 )
2019
29
Synthetic CpG-ODN rapidly enriches immune compartments in neonatal chicks to induce protective immunity against bacterial infections. ( 30674918 )
2019
30
Impact of Delayed Appropriate Antibiotic Therapy on Patient Outcomes by Antibiotic Resistance Status From Serious Gram-negative Bacterial Infections. ( 30665490 )
2019
31
Bacteria-Responsive Nanoliposomes as Smart Sonotheranostics for Multidrug Resistant Bacterial Infections. ( 30657302 )
2019
32
Presepsin: A promising biomarker for the detection of bacterial infections. ( 30611989 )
2019
33
Synergistic treatment strategies to combat resistant bacterial infections using Schiff base modified nanoparticulate - hydrogel system. ( 30573245 )
2019
34
Smart wound dressing based on κ-carrageenan/locust bean gum/cranberry extract for monitoring bacterial infections. ( 30553333 )
2019
35
Bacteriophages: an overview of the control strategies against multiple bacterial infections in different fields. ( 30485461 )
2019
36
The correlation of crystalline and elemental composition of urinary stones with a history of bacterial infections: TXRF, XRPD and PCR-DGGE studies. ( 30483831 )
2019
37
Pharmacokinetic Characteristics and Limited Sampling Strategies for Therapeutic Drug Monitoring of Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections. ( 30299430 )
2019
38
PEDOT/FHA nanocomposite coatings on newly developed Ti-Nb-Zr implants: Biocompatibility and surface protection against corrosion and bacterial infections. ( 30813050 )
2019
39
BMP2-loaded titania nanotubes coating with pH-responsive multilayers for bacterial infections inhibition and osteogenic activity improvement. ( 30763789 )
2019
40
Common NOD2 Risk Variants as Major Susceptibility Factors for Bacterial Infections in Compensated Cirrhosis. ( 30702490 )
2019
41
Applicability of Sepsis-3 criteria and quick Sequential Organ Failure Assessment in patients with cirrhosis hospitalised for bacterial infections. ( 30276961 )
2019
42
Radiosynthesis and validation of [Carboxy-11 C]4-Aminobenzoic acid ([11 C]PABA), a PET radiotracer for imaging bacterial infections. ( 30089334 )
2019
43
Multidrug-resistant bacterial infections in patients with liver cirrhosis in a tertiary referral hospital. ( 30342782 )
2018
44
Novel PET and Near Infrared Imaging Probes for the Specific Detection of Bacterial Infections Associated With Cardiac Devices. ( 29680350 )
2018
45
SM22 is required for the maintenance of actin-rich structures generated during bacterial infections. ( 29778753 )
2018
46
Q969R polymorphism in NLRP3 is associated with immune responses to vaccination against bacterial infections in pigs. ( 29770580 )
2018
47
Bacterial testing of platelets - has it prevented transfusion-transmitted bacterial infections in Australia? ( 28952159 )
2018
48
Epigenetic regulation in bacterial infections: targeting histone deacetylases. ( 28971711 )
2018
49
Versatility of targeted antibiotic-loaded gold nanoconstructs for the treatment of biofilm-associated bacterial infections. ( 29025325 )
2018
50
Zinc finger protein 365 is a new maternal LPS-binding protein that defends zebrafish embryos against gram-negative bacterial infections. ( 29042450 )
2018